Summary

3.89 -0.19(-4.66%)12/12/2025
Minerva Neurosciences, Inc. (NERV)

Key Facts


Historical Returns
1 Day1 Week1 Month3 Months6 Months1 Year5 Years
-4.66-9.91-13.6966.38162.4280.18-87.81


Price Chart Compare
Last 730 data points are shown. To view all data, Upgrade to PRO plan!


Fundamental Ratings
CategoryRating
Main RatingB-
Recommended RatingNeutral
DCFBuy
ROEStrong Sell
ROAStrong Buy
Debt/EquityStrong Sell
P/ENeutral
P/BStrong Sell


Earnings
  • NERV reported last earnings on 2025-11-05 after the market.
  • An EPS of $-0.36 was observed compared to an estimated EPS of $-0.35, resulting in a surprise value of $-0.01.
  • A revenue of $0 million was observed compared to an estimated revenue of $0 million, resulting in a surprise value of $0 Million.


    • Key Statistics
    Trading Data
    Close3.89
    Open4.06
    High4.06
    Low3.86
    Volume35,808
    Change-0.19
    Change %-4.66
    Avg Volume (20 Days)99,975
    Volume/Avg Volume (20 Days) Ratio0.36
    52 Week Range1.28 - 12.46
    Price vs 52 Week High-68.78%
    Price vs 52 Week Low203.91%
    Range0.00
    Gap Up/Down-0.19
    Profitibility
    Market Capitalization (Mln)26
    Revenue per share0.0056
    Net Income per share1.4836
    Dividend Yield0.0000
    Dividend Share0.00%
    Valuations
    Enterprise Value0.00%
    PE Ratio2.7905
    PB Ratio0.0000
    PTB Ratio0.0000
    Liquidity
    Debt/Equity Ratio0.0000
    Net Debt/EBIDTA Ratio0.0000
    Current Ratio0.0000
    Enterprise Value and Cash Flow
    EV/Sales Ratio0.0000
    EV/EBIDTA Ratio0.0000
    EV/Free Cash Flow Ratio0.0000


    News
    11/19 08:30 EST - globenewswire.com
    Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors
    Dr. Inder Kaul, CMO of Draig Therapeutics, joins Minerva Neuroscience Board of Directors, and will also serve as a consultant for roluperidone development.
    11/05 07:30 EST - globenewswire.com
    Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
    BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third...
    10/21 08:00 EST - globenewswire.com
    Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation for US Commercial Launch, if Approved
    Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have defined a path forward for roluperidone's clinical development and NDA resubmission.
    08/14 16:35 EST - globenewswire.com
    Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
    FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia
    05/13 07:30 EST - globenewswire.com
    Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
    BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter...
    02/25 07:00 EST - globenewswire.com
    Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
    BURLINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth...
    11/05 07:30 EST - globenewswire.com
    Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
    BURLINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the third...
    05/06 13:01 EST - zacks.com
    Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock?
    Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
    05/01 07:30 EST - globenewswire.com
    Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
    BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first...
    02/22 07:00 EST - globenewswire.com
    Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
    BURLINGTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth...
    11/07 07:30 EST - globenewswire.com
    Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
    BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the third quarter...
    08/23 04:05 EST - seekingalpha.com
    Minerva Neurosciences: There's Probably Time For One More Rally
    Minerva Neurosciences has raised $20M through a private placement at a premium to market prices. Boehringer Ingelheim participated in the private placement. Boehringer is itself developing a drug for schizophrenia, albeit for cognitive impairments associated with schizophrenia. NERV has six months...
    08/01 07:30 EST - globenewswire.com
    Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
    BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the second...
    06/28 08:30 EST - globenewswire.com
    Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
    BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it has agreed to sell an aggregate of 1,425,000 shares...
    06/09 10:57 EST - zacks.com
    Here's Why Minerva Neurosciences (NERV) Is a Great 'Buy the Bottom' Stock Now
    Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential...
    06/05 14:11 EST - zacks.com
    Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
    Nasdaq ETF marked first six-week rally since Jan 2020. These stocks gained more than 100% during this time frame.
    05/19 17:34 EST - seekingalpha.com
    Minerva Neurosciences: Up About 250 Percent Since April With An FDA Catalyst Ahead
    NERV has once again run on the submission of an NDA for roluperidone for the treatment of negative symptoms in schizophrenia. There will be no Refusal to File letter this time, with NERV using a dispute resolution process to its advantage.
    05/18 13:02 EST - zacks.com
    What Makes Minerva Neurosciences (NERV) a New Buy Stock
    Minerva Neurosciences (NERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
    05/15 07:30 EST - globenewswire.com
    Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
    BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the first quarter...

    Market News ×
    Loading news…